PDCD1 and cervical carcinoma: Focusing on cervical cancer, patients with a CPS greater than 1 who received PD-1 inhibitor therapy had better OS compared to those who did not (pooled HR: 0.65, 95% CI: 0.53-0.80; p <.001; Supplementary Figure 2D) (21, 22).